Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
2012 1
2013 3
2014 2
2015 2
2016 3
2017 2
2018 1
2019 2
2020 2
2021 6
2022 4
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.
Young KG, McInnes EH, Massey RJ, Kahkoska AR, Pilla SJ, Raghavan S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD PDMI. Young KG, et al. Among authors: mcgovern ap. Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w. Commun Med (Lond). 2023. PMID: 37794166 Free PMC article.
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, Hattersley AT, Jones AG, Shields BM; MASTERMIND consortium. Dennis JM, et al. Among authors: mcgovern ap. Lancet Digit Health. 2022 Dec;4(12):e873-e883. doi: 10.1016/S2589-7500(22)00174-1. Lancet Digit Health. 2022. PMID: 36427949 Free article.
Precision medicine in type 2 diabetes: A systematic review of treatment effect heterogeneity for GLP1-receptor agonists and SGLT2-inhibitors.
Young KG, McInnes EH, Massey RJ, Kahkohska AR, Pilla SJ, Raghaven S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD Precision Medicine in Diabetes Initiative Consortium. Young KG, et al. Among authors: mcgovern ap. medRxiv [Preprint]. 2023 Apr 22:2023.04.21.23288868. doi: 10.1101/2023.04.21.23288868. medRxiv. 2023. PMID: 37131814 Free PMC article. Updated. Preprint.
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, Holman RR, Bowden J, Hattersley AT, Pearson ER, Jones AG, Shields BM, McKinley TJ, Dennis JM; MASTERMIND consortium. Cardoso P, et al. Among authors: mcgovern ap. Diabetologia. 2024 May;67(5):822-836. doi: 10.1007/s00125-024-06099-3. Epub 2024 Feb 22. Diabetologia. 2024. PMID: 38388753 Free PMC article.
Type 2 diabetes: A protective factor for COPD?
Rayner LH, McGovern AP, Sherlock J, Gatenby P, Correa A, Creagh-Brown B, de Lusignan S. Rayner LH, et al. Among authors: mcgovern ap. Prim Care Diabetes. 2018 Oct;12(5):438-444. doi: 10.1016/j.pcd.2018.05.002. Epub 2018 May 26. Prim Care Diabetes. 2018. PMID: 29843977
34 results